Intravenous gammaglobulin-induced chronic renal failure in a patient with multiple myeloma.
Although generally well tolerated there have been a number of reports of acute deterioration in renal function with the use of intravenous immune globulin (IVIG). It is of generally limited duration and is self-limiting. We for the first time have described a patient with multiple myeloma and normal renal function who developed chronic renal failure shortly after IVIG treatment in a patient with no pre-existing renal disease. We would therefore recommend the cautious use of IVIG in patients with normal renal function or with pre-existing renal disease. Renal function should also be assessed both prior to and after application of IVIG.
Sevinc
Alper
A
Department of Medical Oncology, School of Medicine, Gaziantep University, Gaziantep Oncology Hospital, Gaziantep 27310, Turkey. sevinc@gantep.edu.tr
Camci
Celalettin
C
Buyukberber
Suleyman
S
Akgul
Bulent
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D007167:Immunotherapy / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous